Goksu, Suleyman Yasin, Ozer, Muhammet, Goksu, Busra B., Wang, Rong, Khatib, Jude, Patel, Prapti A., Vusirikala, Madhuri, Cole, Suzanne, Seyhanli, Ahmet, Collins, Robert H., Chung, Stephen, Zeidan, Amer M., and Madanat, Yazan F.
Race and ethnic backgrounds affect the disease characteristics and clinical outcomes in many cancers, including acute myeloid leukemia; however, the association of race/ethnicity on myelodysplastic syndrome (MDS) is still controversial. Therefore, we aimed to study the impact of race/ethnicity on the disease characteristics and survival outcomes in patients with MDS. Adult patients with MDS diagnosed in 2004–2016 were selected using the SEER database. Race/ethnicity was categorized as non-Hispanic White (NHW), non-Hispanic Black (NHB), and Hispanic. Hispanic and NHB patients had significantly lower incidence rate ratio (IRR) in age group ≥01 years (p <.001) compared to NHW; however, in the age group <50 years, NHB patients had significantly higher IRR with an increased incidence rate of 49%. NHB patients had better overall survival than Hispanic and NHW patients (p <.001), even after adjusting for confounding variables. MDS have significant differences in age at diagnosis, disease risk, and survival outcomes based on racial/ethnic backgrounds. [ABSTRACT FROM AUTHOR]